"Increase in desferrioxamine-chelatable iron levels"
Public release date: 20-May-2008
Contact: Keely Savoie
ksavoie@
thoracic.org
212-315-8620
American Thoracic Society
New treatment gives hope for pulmonary fibrosis patients
ATS 2008, TORONTO—Patients with idiopathic pulmonary fibrosis (IPF)
may have a new treatment option, according to researchers in Japan.
In a Phase III, double-blind, placebo-controlled clinical trial, the
investigators discovered that a daily dose of pirfenidone could slow
the progression of IPF, reducing the loss of lung capacity. The
results will be announced at the American Thoracic Society’s 2008
International Conference in Toronto on Tuesday, May 20.